Merck & Co. Buys Out OncoImmune For Phase III COVID-19 Therapy
Deal snapshot: For $425m up front, the pharma obtains a Phase III recombination fusion protein that shows ability to improve hospitalized patients’ clinical status and reduce risk of death.
You may also be interested in...
Regeneron's antibody cocktail prevented deaths and mechanical ventilation in hospitalized patients on low-flow oxygen. Also, Pfizer and BioNTech will supply an additional 100m doses of the companies' COVID-19 vaccine to the US government for $1.95bn, while Merck & Co signed a contract for its COVID-19 treatment MK-7110.
Pharma’s latest partnerships focus on Duchenne muscular dystrophy with Precision Biosciences, protein degradation with Seed. Bristol and Schrodinger team in computational drug discovery.
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.